▟ Vinebot intrinsic value, daily

← back

GL Globe Life

insurance · valued with opus medium conviction · deep-dived 2026-11-18

HOLD
Intrinsic value$127.11
Price (at call)$158.04
Margin of safety -19.6%
vs market (rating basis) +2.3%

High-return niche insurer and steady buyback compounder; still priced above normalized value despite the pullback.

The story

Globe Life is a niche life and supplemental health insurer selling low-face-value policies to middle-income households through captive agencies, with steady premium growth (~4.7% CAGR) and operating margins rising from 22.8% to 26.3%. Trailing ROE of 19.8% is inflated because unrealized bond losses (AOCI) depress reported book, so the underlying return is closer to the mid-teens. The balance sheet is conservative, liability-driven and long-duration, and life underwriting is not very cyclical. The ongoing overhang is agency-practice scrutiny and the regulatory probes that followed it.

Drivers are unchanged from October: margin gains and a 19.8% trailing ROE support 17%, but much of that headline comes from an AOCI-shrunken book rather than better economics, so I won't chase the peak. Heavy buybacks keep book growth modest, and the terminal 4% stays below the 5.1% risk-free rate. The roughly 6% fall in the share price is market movement, not new fundamental information.

Value drivers

Return on equity (normalized)17.0%
Book-value growth (Y1)6.0%
Terminal book growth4.0%
Beta0.95
Failure probability2.0%
Cost of equity9.4%

Valuation bridge

PV of excess returns2.33B
PV of terminal excess1.48B
Equity value9.59B
÷ shares → per share$127.11

Projected excess returns on equity

YrBook equityROEExcess returnPV
15.97B 17.0%455.38M 416.34M
26.33B 16.4%443.14M 370.41M
36.70B 15.8%426.90M 326.24M
47.07B 15.1%406.45M 283.98M
57.45B 14.5%381.60M 243.76M
67.83B 13.9%352.20M 205.69M
78.21B 13.3%318.12M 169.86M
88.59B 12.6%279.28M 136.33M
98.98B 12.0%235.61M 105.16M
109.36B 11.4%187.12M 76.35M

Key risks

  • Agency misconduct allegations and regulatory or legal action damaging recruiting and sales at American Income
  • Higher policy lapses or worse mortality/morbidity in health lines
  • Large AOCI swings that distort book value and capital flexibility if rates move sharply

Catalysts

  • Resolution of DOJ/SEC inquiries removing the governance discount
  • Continued buybacks and margin expansion lifting EPS and per-share book

History

DatePriceIntrinsicMoSRating
2026-11-18$158.04 $127.11 -19.6% HOLD
2026-10-16$167.59 $123.64 -26.2% HOLD
2026-09-15$172.92 $135.52 -21.6% HOLD
2026-08-13$177.91 $125.79 -29.3% HOLD
2026-07-10$178.86 $127.56 -28.7% HOLD
2026-06-23$175.58 $126.78 -27.8% HOLD